TechnipFMC plc Ordinary Share vs Medpace Holdings Inc — how do they compare? TechnipFMC plc Ordinary Share trades at $69.57 (market cap $27.31B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: TechnipFMC plc Ordinary Share is the larger of the two by market cap, and TechnipFMC plc Ordinary Share pays a 0.29% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TechnipFMC plc Ordinary Share for 1 Days and Medpace Holdings Inc for 14 Days on average.
| FTI | MEDP | |
|---|---|---|
Market Cap | $27.31B | $16.82B |
Volume | 2,496,410 | 223,093 |
Sector | Energy | Health |
52-Week High | $80.08 | $630.19 |
52-Week Low | $35.57 | $393.42 |
Typical Hold Time | 1 Days | 14 Days |
Enterprise Value | $27.56B | $16.44B |
Dividend Yield | 0.29% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
TechnipFMC is an energy technology company providing subsea systems, surface technologies, and related services across the life of oil and gas fields. Its offerings include equipment, controls, installation support, and digital tools for offshore and onshore projects.
Read more on FTI →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →